White Paper

Rare and Orphan Diseases: Choosing a Path to Regulatory Approval and Market Success 

About 7,000 rare or orphan diseases exist today – In the U.S. alone, these diseases affect less than 200,000 people. With a small population to work from, there’s typically a lack of market push from industry investment.

Our white paper explores these challenges and provides regulatory pathway guidance for sponsors and emerging biologics companies engaged in bringing these innovative therapies to market. Topics include:
  • The Orphan Drug Act (ODA) and its Impact
  • Drug development challenges
  • Clinical operation issues
  • Clinical trial outcome hurdles
  • Pricing obstacles
  • And more

Download the white paper.

Who Should Watch?

CEU Credits

Certificate of Attendance

Time: 1 p.m. ET, 12 p.m. CT, 10 a.m. PT
Duration: 1 hour

Download Now